Disc Medicine (IRON) Is Up 7.2% After Advancing Bitopertin Phase 3 Despite FDA Efficacy Concerns
Disc Medicine's stock rose 7.2% after it announced the completion of patient enrollment and dosing in its expanded pivotal Phase 3 APOLLO trial for bitopertin, a drug for erythropoietic and X-linked protoporphyria. This development occurs despite a previous FDA Complete Response Letter citing insufficient efficacy in earlier trials, creating a complex risk-reward profile for the company. The market's reaction reflects a renewed interest in the drug's potential, betting on the success of the Phase 3 data expected in late 2026.
Incyte Corp. stock underperforms Monday when compared to competitors
Incyte Corp. (INCY) stock fell 1.12% on Monday, closing at $94.86, despite a positive trading session for the broader market. This decline concluded a four-day winning streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both saw gains on the same day.
Incyte (INCY) Is Up 6.2% After Positive 54-Week HS and IO Combo Data - What's Changed
Incyte's stock rose 6.2% following positive 54-week Phase 3 data for its oral JAK1 inhibitor povorcitinib in hidradenitis suppurativa, coupled with a new clinical collaboration for a bispecific antibody in colorectal cancer. The company aims to reduce its reliance on Jakafi by diversifying its revenue through this immunology and oncology pipeline. While analysts are cautiously optimistic about new product scaling, Incyte projects significant revenue and earnings growth by 2028, suggesting a potential 4% upside to its current price.
Allspring Global Investments Holdings LLC Buys 112,736 Shares of Incyte Corporation $INCY
Allspring Global Investments Holdings LLC significantly increased its stake in Incyte Corporation (NASDAQ:INCY) during the fourth quarter, buying an additional 112,736 shares for a total of 124,003 shares valued at approximately $12.58 million. This comes as Incyte reported mixed Q4 earnings, missing EPS estimates but exceeding revenue forecasts. Analyst sentiment for Incyte is currently split, with a "Hold" consensus rating and an average price target of $104.89.
Toth Financial Advisory Corp Acquires Shares of 12,280 Incyte Corporation $INCY
Toth Financial Advisory Corp recently acquired 12,280 shares of Incyte Corporation, a biopharmaceutical company, valued at approximately $1.21 million. This comes amidst mixed sentiment for Incyte, with institutional ownership at nearly 97% but significant insider selling reported. Analysts currently rate the stock as a "Hold" with an average target price of $104.89, following a quarter where the company missed EPS estimates but exceeded revenue expectations.
Adagene, Incyte Collaborate on Colorectal Cancer Drug Trial
Adagene and Incyte are launching a Phase 1 study in 2026 to evaluate the combination of muzastotug (anti-CTLA-4 antibody) and INCA33890 (TGFβR2 × PD-1 bispecific) for third-line MSS colorectal cancer, including patients with liver metastases. Incyte will sponsor the trial and supply INCA33890, while Adagene will supply muzastotug. This collaboration aims to broaden treatment options for a challenging immuno-oncology setting and leverage existing preliminary data for both agents.
Wilmington pledged $10M in grants to Incyte
The city of Wilmington had pledged $10 million in grants to Incyte Corporation, adding to $14.8 million in state grants, for the biopharmaceutical company to establish its new headquarters downtown in the Bracebridge I and III buildings. Incyte has since scaled back its plans, leading to renegotiations on the total $24.8 million in taxpayer-backed grants, of which only $5.67 million has been spent so far. City and state officials are in discussions to revise the grant agreements, with Wilmington's $10 million not yet disbursed, while the company plans a smaller presence than originally promised.
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp
The report provides comprehensive insights into the evolving landscape of Non Muscle Invasive Bladder Cancer (NMIBC) treatment therapies, highlighting over 20 companies and 22 therapies in various stages of clinical development. It details several key therapies like TL-532, AU-011, and TARA-002, and discusses recent FDA approvals and clinical trial advancements for NMIBC treatments. The report also addresses market drivers such as the increasing patient population and novel therapies, juxtaposed with barriers like the need for targeted therapy for specific mutations.
Non Muscle Invasive Bladder Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics, Incyte Corp
DelveInsight's "Non Muscle Invasive Bladder Cancer Pipeline Insight, 2026" report provides a comprehensive overview of the clinical development landscape for Non-Muscle Invasive Bladder Cancer (NMIBC), highlighting over 20 companies and 22 treatment therapies in various stages of development. The report details emerging therapies, recent FDA approvals, and ongoing clinical trials by key players like Aura Biosciences, Protara Therapeutics, and Incyte Corp. It also discusses market drivers such as the increasing patient population and barriers like the need for targeted therapies and lack of awareness.
Incyte (INCY) director Edmund Harrigan takes 269-share grant in fees
Incyte director Edmund Harrigan received a grant of 269 shares of common stock as a fully vested restricted stock award. This grant, valued at $94.12 per share, was issued in lieu of quarterly director retainer fees under Incyte’s 2010 Stock Incentive Plan and is compliant with Rule 10b5-1. Following this transaction, Harrigan directly holds 21,122 shares, which includes 2,518 shares from unvested restricted stock units.
Incyte Corp (INCY) board rep logs 421-share RSU fee grant
Incyte Corp (INCY) board representative Julian C. Baker received a grant of 421 restricted stock units (RSUs) in lieu of $40,500 in quarterly director retainer fees. This transaction, reported in a Form 4 SEC filing, represents a routine, compensation-related award and is fully vested. The RSUs are indirectly held by Baker Bros. Advisors LP and affiliated funds, which have voting and dispositive power over the shares.
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Adagene Inc. has announced a clinical collaboration with Incyte to study the combination of muzastotug (ADG126) and INCA33890 in patients with microsatellite stable colorectal cancer (MSS CRC). This collaboration aims to explore a novel treatment approach for MSS CRC, a disease known for its resistance to current immunotherapies, particularly in patients with liver metastases who have limited options and a poor prognosis. The study, sponsored by Incyte, is expected to begin in 2026 and will further validate muzastotug's potential as a backbone therapy for next-generation immuno-oncology combinations.
Incyte HS Data Tests New Leadership And Povorcitinib Growth Potential
Incyte (NasdaqGS:INCY) released positive 54-week Phase 3 data for povorcitinib in moderate to severe hidradenitis suppurativa (HS), demonstrating durable efficacy and improved quality of life. This data is critical for potential regulatory approvals and commercial launch, especially under Incyte's new leadership team. The success of povorcitinib will test the company's ability to diversify beyond its oncology focus and establish a strong presence in immunology and dermatology.
Incyte Corporation (INCY) stock price, news, quote and history
This page provides comprehensive information on Incyte Corporation (INCY) stock, including its current price, historical data, key statistics, and company overview. It details Incyte's biopharmaceutical operations, its various therapeutic products, and pipeline projects. The article also includes performance overviews, analyst insights, earnings trends, and valuation measures for INCY, alongside comparisons to similar biotechnology companies.
Citizens reiterates Incyte stock rating on pipeline progress
Citizens has reiterated a "Market Perform" rating on Incyte Corp. (NASDAQ:INCY) after the company presented updated clinical trial data for povorcitinib at the AAD 2026 Congress, showing sustained efficacy. Incyte filed New Drug Applications for povorcitinib in Q4 2025, with potential peak revenues of up to $1 billion. While the firm believes Incyte's financial position is solid and shares are fairly valued, other analysts have varied opinions, with UBS lowering its price target and Stifel reiterating a "Buy" rating based on different interpretations of recent developments and drug trial data.
Incyte Corp. stock outperforms competitors on strong trading day
Incyte Corp. (INCY) shares rose 1.73% to $95.93 on Thursday, marking its fourth consecutive day of gains. The stock's performance outpaced a mixed market session, with the S&P 500 Index up slightly and the Dow Jones Industrial Average down. This positive movement indicates a strong trading day for Incyte Corp. despite broader market fluctuations.
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Adagene Inc. has announced a clinical collaboration with Incyte to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with microsatellite stable colorectal cancer (MSS CRC). Incyte will sponsor and conduct the Phase 1 study, with Adagene providing clinical supply of muzastotug. This collaboration aims to explore a novel treatment approach for MSS CRC, particularly in patients with liver metastases, enhancing the potential of muzastotug as a backbone immunotherapy.
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP
Adagene (Nasdaq: ADAG) announced the pricing of an underwritten public offering of 18,666,000 American Depositary Shares (ADSs) at US$3.75 per ADS, aiming to raise approximately US$70.0 million in gross proceeds. This pricing matches the 30-day volume-weighted average price. The offering is expected to close on April 6, 2026, and includes participation from new and existing institutional investors.
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Adagene Inc. announced a clinical collaboration with Incyte to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, for treating microsatellite stable colorectal cancer (MSS CRC). The Phase 1 study, sponsored by Incyte, is expected to begin in 2026 and will assess the combination in third-line MSS CRC patients, including those with liver metastases. This collaboration further validates muzastotug's potential as a foundational therapy for next-generation immuno-oncology treatments, aiming to improve response rates and extend survival in a disease resistant to current immunotherapies.
Citizens reiterates Incyte stock rating on pipeline progress
Citizens reiterated a Market Perform rating on Incyte Corp. following updated clinical trial data for povorcitinib, showing deep efficacy in treating hidradenitis suppurativa. The firm believes Incyte's existing portfolio can offset the upcoming ruxolitinib patent cliff, leading to a solid financial position and a fair valuation of its shares, which also benefits from a substantial cash balance. Despite this positive outlook, other analysts like UBS have lowered price targets due to revenue concerns for other products, while Stifel and William Blair have offered varying perspectives on povorcitinib's trial results.
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY
J. Safra Sarasin Holding AG significantly reduced its stake in Incyte Corporation by 80.9% in Q4, selling 35,655 shares. Despite this, other institutional investors, such as Nordea Investment Management, substantially increased their holdings, with institutional ownership nearing 97%. Incyte (NASDAQ: INCY) reported Q4 EPS of $1.80, missing estimates, but revenue still rose by 27.8% to $1.51 billion, and analysts currently express a "Hold" consensus on the stock.
Barclays Maintains Overweight on Incyte (INCY) Mar 2026
Barclays has maintained an Overweight rating on Incyte (INCY) as of March 24, 2026, despite mixed Phase 3 trial results, citing product and pipeline strengths. This decision reinforces Barclays' positive outlook on INCY, an opinion shared by Stifel, which reiterated a Buy rating and a $120 price target. The maintained rating coincided with a 4.06% price increase for INCY, and Meyka AI also assigns INCY an 'A' grade based on various financial and market factors.
Incyte Announces Upcoming Resignation of Board Member Schaffert
Incyte Corporation announced that board member Susanne Schaffert will resign from the company's Board of Directors effective April 15, 2026. Her resignation, after serving since 2022, is not due to any disagreement over operations or policies, indicating a routine governance change. Analysts currently hold a Buy rating on INCY stock with a $123.00 price target.
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Incyte Corp. (INCY) stock rose 4.20% on Tuesday, closing at $94.12, marking its second consecutive day of gains. Despite this increase, the stock underperformed compared to the broader market, as the S&P 500 Index (SPX) gained 2.91% and the Dow Jones Industrial Average (DJIA) rose 2.49% on the same favorable trading day. The article highlights Incyte's daily stock performance in relation to major market indices.
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
The 2026 American Academy of Dermatology meeting highlighted advancements in next-generation skin drugs from Sanofi, Incyte, Roivant, and Alumis. While Sanofi's amlitelimab showed weaker efficacy compared to Dupixent in atopic dermatitis, Incyte's povorcitinib delivered robust data for hidradenitis suppurativa. Roivant reinforced brepocitinib's profile in dermatomyositis, and Alumis presented promising Phase 3 results for envudeucitinib in plaque psoriasis, with a planned FDA filing in late 2026.
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
UBS has increased its price target for Incyte Corp (INCY) due to anticipated sales and earnings growth. This adjustment suggests a positive outlook on the company's financial performance.
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026
Susanne Schaffert has informed Incyte that she will resign from its Board of Directors, with her resignation becoming effective on April 15, 2026. Her departure is stated not to be due to any disagreements with the company's operations, policies, or practices. She has been a member of the Board since 2022, and a replacement has not yet been disclosed.
Incyte board member Susanne Schaffert to step down in April
Incyte Corporation announced that board member Susanne Schaffert will resign effective April 15, 2026. Her departure is not due to disagreements. Incyte has seen significant financial momentum, with shares returning 49% over the past year, while also facing mixed analyst reactions regarding its drug pipeline, particularly for povorcitinib and products Opzelura and Jakafi.
Incyte board member Susanne Schaffert to step down in April
Susanne Schaffert has announced her resignation from Incyte's board of directors, effective April 15, 2026, a decision not related to disagreements with the company. Incyte has shown strong financial performance, despite mixed analyst reactions to recent drug trial results and some adjusted price targets. The company also recently appointed Pablo J. Cagnoni as President and Global Head of Research and Development.
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
Incyte (INCY) announced strong 54-week data from its late-stage STOP-HS program, demonstrating substantial and sustained efficacy of povorcitinib in patients with moderate-to-severe hidradenitis suppurativa (HS). The data, presented at the American Academy of Dermatology Annual Meeting 2026, reinforces povorcitinib’s potential as a differentiated oral JAK1 inhibitor and supports ongoing regulatory review. Incyte also reported impressive progress in its efforts to diversify its portfolio, with top-line phase III data for povorcitinib in vitiligo and prurigo nodularis expected in mid-2026 and Q4 2026, respectively.
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Incyte announced positive 54-week data for povorcitinib in treating moderate to severe hidradenitis suppurativa (HS), demonstrating substantial and durable clinical efficacy. The Phase 3 STOP-HS program showed clinically meaningful improvements in HiSCR50, HiSCR75, and HiSCR100 rates, along with reductions in inflammatory lesions and improved quality-of-life measures. The safety profile remained consistent with previous reports, and regulatory applications for povorcitinib in HS are currently under review.
Understanding the Setup: (INCY) and Scalable Risk
This article provides an analysis of Incyte Corporation (NASDAQ: INCY), highlighting divergent sentiment across different time horizons and elevated downside risk. It presents AI-generated trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis aims to help traders understand potential setups and scalable risks associated with INCY.
Stifel reiterates Incyte stock rating on hidradenitis drug data
Stifel reiterated a Buy rating and $120 price target for Incyte Corporation (NASDAQ:INCY) after reviewing extended clinical trial data for its drug candidate povorcitinib, indicated for hidradenitis suppurativa. The data showed impressive responses and favorable safety, with Stifel suggesting the drug's utility is currently underestimated. This positive outlook is supported by Incyte's strong cash position, aiding further clinical development.
NOVARTIS AG : Deutsche Bank reiterates its Buy rating
Deutsche Bank has reiterated its "Buy" rating for Novartis AG, with Emmanuel Papadakis maintaining a target price of CHF 135. The news highlights recent developments for Novartis, including the US FDA's approval of a higher dose for Biogen's genetic disorder drug, and positive trial results for Novartis's own kidney disease treatments. Novartis AG is a global leader in pharmaceuticals, with significant operations in oncology, immunology, and cardiovascular diseases.
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
This article reviews the Q4 earnings of several biotechnology stocks, highlighting Incyte's performance against its peers. It discusses the high-risk, high-reward nature of the biotechnology industry and details the Q4 results for Incyte, Novavax, United Therapeutics, BioMarin Pharmaceutical, and Moderna, including revenue figures, analyst beats/misses, and stock performance. The article also provides a brief market update on shifting investor concerns related to AI and geopolitical risks.
Incyte's Long-term Relief in Skin Disease Drug Success & AI Drug Development: An Industry Shift
Incyte's experimental drug, povorcitinib, has shown promising long-term results in late-stage trials for hidradenitis suppurativa. Concurrently, Insilico Medicine and Eli Lilly are collaborating on a $2.75 billion AI-driven drug development initiative. Eli Lilly is also advocating for changes in NHS drug pricing to encourage UK investments.
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
This article reviews Q4 earnings for biotechnology stocks, highlighting Incyte (NASDAQ: INCY) and examining its performance against peers like Novavax, United Therapeutics, BioMarin Pharmaceutical, and Moderna. While the industry saw strong Q4 revenues, individual stock performances varied, with some companies beating estimates and others missing, often leading to stock price declines despite positive results. The piece also briefly touches on market anxieties about AI and geopolitical risks shifting investor focus.
(INCY.O) | Stock Price & Latest News
This article provides a company profile, financial data, and recent news headlines for Incyte Corp (INCY.O). Key news includes late-stage trial results for a skin disease drug, forecasts for Opzelura revenue, an update on a blood cancer therapy trial, and the FDA approval of an eczema cream for pediatric patients. The company is a biopharmaceutical firm focused on hematology/oncology and inflammation/autoimmunity.
After a year, Incyte’s oral HS drug showed durable gains in Phase 3
Incyte announced positive 54-week data from its Phase 3 STOP-HS clinical trial program for povorcitinib, an oral drug for moderate to severe hidradenitis suppurativa (HS). The data showed durable and clinically meaningful improvements in disease activity and quality of life measures, with a consistent safety profile. These results support the ongoing regulatory applications for povorcitinib in the U.S. and Europe, positioning it as a potential first-in-class oral treatment for HS.
Once-daily KT-621 cut dermatitis severity 63% in early trial
Kymera Therapeutics presented positive Phase 1b results for its oral STAT6 degrader KT-621 in moderate-to-severe atopic dermatitis patients. The trial showed a median STAT6 degradation of up to 98% in blood and a 63% mean reduction in EASI scores after 28 days of once-daily dosing. With favorable safety, parallel Phase 2b trials for atopic dermatitis and asthma are ongoing, with data expected by mid and late-2027, respectively.
Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in Incyte Corporation (NASDAQ:INCY) by 627.8% in Q4, acquiring 186,790 shares valued at $18.45 million. This investment comes amidst notable insider selling from top executives and after the company missed Q4 EPS estimates but beat revenue expectations. Analysts currently have a "Hold" rating on Incyte with a consensus price target of $104.89.
Fairvoy Private Wealth LLC Acquires 24,865 Shares of Incyte Corporation $INCY
Fairvoy Private Wealth LLC significantly increased its stake in Incyte Corporation (NASDAQ:INCY) by 468.8% in Q4, purchasing 24,865 shares to hold a total of 30,169 shares valued at $2.98 million. Despite this institutional buying, Wall Street analysts have a mixed outlook, with a consensus "Hold" rating and a target price of $104.89, while some have recently lowered their price targets. Insider selling by executives was also reported, though institutional investors collectively own almost 97% of the company's stock.
Fairvoy Private Wealth Boosts Incyte Corporation Holdings
Fairvoy Private Wealth LLC significantly increased its holdings in Incyte Corporation (NASDAQ:INCY) by 468.8% during the fourth quarter, adding 24,865 shares. This substantial investment, now totaling 30,169 shares worth $2.98 million, signals growing institutional confidence in Incyte's pipeline and commercial potential, particularly its flagship product Jakafi. The move suggests the hedge fund sees strong future performance prospects for the biopharmaceutical company despite recent underperformance.
The Bull Case For Incyte (INCY) Could Change Following Its U.S. Commercial Leadership Shake-Up – Learn Why
Incyte recently reorganized its leadership, consolidating U.S. commercial operations under Mohamed Issa and expanding other roles, which analysts believe could transform the company's investment narrative. These changes aim to strengthen the link between R&D and commercial execution, particularly for key drugs like Opzelura and povorcitinib. The company faces the challenge of diversifying revenue and converting its pipeline into sustainable income before potential competition affects its main revenue driver, Jakafi.
The Bull Case For Incyte (INCY) Could Change Following Its U.S. Commercial Leadership Shake-Up – Learn Why
Incyte recently announced a leadership reshuffle, consolidating U.S. commercial operations under Mohamed Issa and expanding roles for Pablo J. Cagnoni and Steven Stein. These changes aim to strengthen the connection between R&D and commercial execution, particularly focusing on late-stage data readouts for treatments like Opzelura and povorcitinib. The company's investment narrative centers on diversifying its revenue base beyond Jakafi, with projections of $5.9 billion revenue by 2028, but investors are keenly watching if these moves can address the upcoming patent risk for Jakafi.
Incyte Corp. stock outperforms competitors despite losses on the day
Incyte Corp. (INCY) shares decreased by 2.12% to $90.30 on Friday, despite a challenging day for the broader stock market where the S&P 500 Index and Dow Jones Industrial Average also saw significant drops. This dip ended a three-day winning streak for Incyte's stock. The article highlights that even with losses, Incyte's performance outpaced its competitors.
Vanguard disaggregates holdings; reports 0% in Incyte (INCY)
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Incyte (INCY) common stock. This change is due to an internal realignment effective January 12, 2026, which now requires certain Vanguard subsidiaries to report their holdings separately, in reliance on SEC Release No. 34-39538. The parent entity, The Vanguard Group, no longer reports beneficial ownership for these disaggregated holdings.
Wealth Enhancement Advisory Services LLC Buys 20,988 Shares of Incyte Corporation $INCY
Wealth Enhancement Advisory Services LLC increased its stake in Incyte Corporation by 19.7%, purchasing an additional 20,988 shares to bring its total holdings to 127,777 shares valued at approximately $13.71 million. This increase makes their holding about 0.07% of the company's stock. Insider transactions show significant sales by Pablo J. Cagnoni and Mohamed Khairie Issa, while analysts maintain a "Hold" consensus rating with a target price of $104.89.
Incyte Japan gains approval for Minjuvi with rituximab and lenalidomide to treat relapsed follicular lymphoma
Incyte Japan has received approval for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for the treatment of relapsed or refractory follicular lymphoma. This approval provides a new treatment option for adult patients in Japan who have not responded to prior therapies, offering a potential advancement in their care.
INCYTE (NASDAQ: INCY) EVP sees 537 shares withheld to cover RSU taxes
INCYTE CORP EVP, Matteo Trotta, had 537 shares of common stock withheld at $92.23 per share to cover tax obligations related to previously granted restricted stock units. This is a routine tax withholding share disposition and not a market sale. Following this transaction, Trotta directly holds 14,882 common shares, which includes 11,160 unvested restricted stock units.
